Cellectis SA Sponsored ADR
(NASDAQ : CLLS)

( )
CLLS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-1.94%88.651.3%$803.98m
AMGNAmgen Inc.
-0.76%185.501.2%$628.99m
GILDGilead Sciences, Inc.
-2.14%65.550.9%$482.29m
BIIBBiogen Inc.
-4.17%321.171.3%$427.44m
ILMNIllumina, Inc.
-1.77%296.883.5%$311.35m
REGNRegeneron Pharmaceuticals, Inc.
-0.92%418.622.6%$290.18m
VRTXVertex Pharmaceuticals Incorporated
-2.55%183.061.9%$253.58m
ALXNAlexion Pharmaceuticals, Inc.
-1.76%127.552.0%$219.68m
SRPTSarepta Therapeutics, Inc.
-2.87%136.5415.4%$152.33m
AAgilent Technologies, Inc.
-0.83%77.911.6%$150.84m
EXASExact Sciences Corporation
-0.42%83.2825.3%$132.28m
INCYIncyte Corporation
-0.49%83.332.5%$111.93m
ARRYArray BioPharma Inc.
-1.99%22.718.2%$108.01m
EXELExelixis, Inc.
-0.09%21.226.4%$82.07m
NBIXNeurocrine Biosciences, Inc.
-2.58%77.315.1%$77.22m

Company Profile

Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.